SE453514B - Sett att bestemma deoxitymidinkinas-dtk-isoenzymnivaer i kroppsvetska eller cellprov och anvendningen av forfarandet for isoenzymtypning - Google Patents

Sett att bestemma deoxitymidinkinas-dtk-isoenzymnivaer i kroppsvetska eller cellprov och anvendningen av forfarandet for isoenzymtypning

Info

Publication number: SE453514B
Authority: SE; Sweden
Prior art keywords: dtk; isoenzyme; concentration; substrate; serum
Prior art date: 1982-05-14

Application number

SE8203041A

Other languages

English (en)

Swedish (sv)

Other versions

SE8203041L (sv

Inventor

Jan-Simon Gronowitz

Clas Fredrik R Kellander

Original Assignee

Gronowitz Jan Sim0N

Clas Fredrik R Kellander

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-05-14

Filing date

1982-05-14

Publication date

1988-02-08

1982-05-14 Application filed by Gronowitz Jan Sim0N, Clas Fredrik R Kellander filed Critical Gronowitz Jan Sim0N

1982-05-14 Priority to SE8203041A priority Critical patent/SE453514B/sv

1983-05-10 Priority to AU15540/83A priority patent/AU551176B2/en

1983-05-10 Priority to PCT/SE1983/000190 priority patent/WO1983004054A1/fr

1983-05-10 Priority to JP58501735A priority patent/JPS59500796A/ja

1983-05-10 Priority to US06/576,375 priority patent/US4637977A/en

1983-05-10 Priority to AT83850122T priority patent/ATE33504T1/de

1983-05-10 Priority to EP83850122A priority patent/EP0094923B1/fr

1983-05-10 Priority to DE8383850122T priority patent/DE3376272D1/de

1983-05-13 Priority to CA000428172A priority patent/CA1199858A/fr

1983-05-13 Priority to ES522376A priority patent/ES8402876A1/es

1983-11-15 Publication of SE8203041L publication Critical patent/SE8203041L/

1984-01-13 Priority to FI840134A priority patent/FI77895C/fi

1984-01-13 Priority to NO840117A priority patent/NO165599C/no

1984-01-13 Priority to DK016384A priority patent/DK167692B1/da

1988-02-08 Publication of SE453514B publication Critical patent/SE453514B/sv

Links

238000000034 method Methods 0.000 title claims abstract description 25
239000007788 liquid Substances 0.000 title 1
230000000694 effects Effects 0.000 claims abstract description 38
239000000758 substrate Substances 0.000 claims abstract description 25
201000010099 disease Diseases 0.000 claims abstract description 23
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 23
206010028980 Neoplasm Diseases 0.000 claims abstract description 20
108010044467 Isoenzymes Proteins 0.000 claims abstract description 14
229910019142 PO4 Inorganic materials 0.000 claims abstract description 11
239000010452 phosphate Substances 0.000 claims abstract description 11
208000015181 infectious disease Diseases 0.000 claims abstract description 10
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract description 10
239000007853 buffer solution Substances 0.000 claims abstract description 9
238000003745 diagnosis Methods 0.000 claims abstract description 6
230000001404 mediated effect Effects 0.000 claims abstract description 5
241000700588 Human alphaherpesvirus 1 Species 0.000 claims abstract description 4
241001465754 Metazoa Species 0.000 claims abstract description 3
210000001124 body fluid Anatomy 0.000 claims abstract description 3
239000010839 body fluid Substances 0.000 claims abstract description 3
229910052736 halogen Inorganic materials 0.000 claims abstract description 3
230000000903 blocking effect Effects 0.000 claims description 3
241000700605 Viruses Species 0.000 claims description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
108090000623 proteins and genes Proteins 0.000 claims 1
230000009385 viral infection Effects 0.000 abstract description 7
238000012544 monitoring process Methods 0.000 abstract description 6
230000035945 sensitivity Effects 0.000 abstract description 5
238000005259 measurement Methods 0.000 abstract description 2
210000002966 serum Anatomy 0.000 description 47
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 18
102000004190 Enzymes Human genes 0.000 description 17
108090000790 Enzymes Proteins 0.000 description 17
206010027476 Metastases Diseases 0.000 description 16
239000012530 fluid Substances 0.000 description 14
238000003556 assay Methods 0.000 description 11
201000011510 cancer Diseases 0.000 description 11
238000006243 chemical reaction Methods 0.000 description 11
239000000243 solution Substances 0.000 description 9
208000017604 Hodgkin disease Diseases 0.000 description 8
208000010747 Hodgkins lymphoma Diseases 0.000 description 8
239000000203 mixture Substances 0.000 description 8
230000003612 virological effect Effects 0.000 description 8
210000004027 cell Anatomy 0.000 description 7
206010000830 Acute leukaemia Diseases 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
208000036142 Viral infection Diseases 0.000 description 6
238000001514 detection method Methods 0.000 description 6
208000020816 lung neoplasm Diseases 0.000 description 6
230000036210 malignancy Effects 0.000 description 6
230000003211 malignant effect Effects 0.000 description 6
206010058467 Lung neoplasm malignant Diseases 0.000 description 5
238000010790 dilution Methods 0.000 description 5
239000012895 dilution Substances 0.000 description 5
201000005202 lung cancer Diseases 0.000 description 5
239000003550 marker Substances 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
230000007306 turnover Effects 0.000 description 5
241000701074 Human alphaherpesvirus 2 Species 0.000 description 4
241000701085 Human alphaherpesvirus 3 Species 0.000 description 4
230000002596 correlated effect Effects 0.000 description 4
208000032839 leukemia Diseases 0.000 description 4
238000012360 testing method Methods 0.000 description 4
241001529453 unidentified herpesvirus Species 0.000 description 4
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 3
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
238000011534 incubation Methods 0.000 description 3
208000037821 progressive disease Diseases 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
208000028018 Lymphocytic leukaemia Diseases 0.000 description 2
208000030289 Lymphoproliferative disease Diseases 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
230000003622 anti-hsv Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
239000012928 buffer substance Substances 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
201000006747 infectious mononucleosis Diseases 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000001589 lymphoproliferative effect Effects 0.000 description 2
239000000463 material Substances 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
238000005070 sampling Methods 0.000 description 2
230000028327 secretion Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
238000004809 thin layer chromatography Methods 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
BOFUZZAQNVYZFF-UHFFFAOYSA-N 2-(3-chlorophenyl)-3-methylmorpholine Chemical compound CC1NCCOC1C1=CC=CC(Cl)=C1 BOFUZZAQNVYZFF-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
208000004736 B-Cell Leukemia Diseases 0.000 description 1
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
208000034657 Convalescence Diseases 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
241000282412 Homo Species 0.000 description 1
208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
208000004068 Morbillivirus Infections Diseases 0.000 description 1
241000202934 Mycoplasma pneumoniae Species 0.000 description 1
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
206010037151 Psittacosis Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
RZCIEJXAILMSQK-JXOAFFINSA-N TTP Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 RZCIEJXAILMSQK-JXOAFFINSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000003602 anti-herpes Effects 0.000 description 1
238000003705 background correction Methods 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
230000001925 catabolic effect Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
239000003480 eluent Substances 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
229960004716 idoxuridine Drugs 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
206010024378 leukocytosis Diseases 0.000 description 1
238000007449 liver function test Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000005265 lung cell Anatomy 0.000 description 1
208000003747 lymphoid leukemia Diseases 0.000 description 1
238000003760 magnetic stirring Methods 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
125000003835 nucleoside group Chemical group 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
201000000901 ornithosis Diseases 0.000 description 1
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000004064 recycling Methods 0.000 description 1
201000005404 rubella Diseases 0.000 description 1
238000011896 sensitive detection Methods 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
208000000587 small cell lung carcinoma Diseases 0.000 description 1
238000011895 specific detection Methods 0.000 description 1
239000012086 standard solution Substances 0.000 description 1
-1 thymidine anion Chemical class 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/50—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving creatine phosphokinase

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Wood Science & Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
Analytical Chemistry (AREA)
Biotechnology (AREA)
Physics & Mathematics (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Enzymes And Modification Thereof (AREA)
Saccharide Compounds (AREA)

SE8203041A 1982-05-14 1982-05-14 Sett att bestemma deoxitymidinkinas-dtk-isoenzymnivaer i kroppsvetska eller cellprov och anvendningen av forfarandet for isoenzymtypning SE453514B (sv)

Priority Applications (13)

Application Number	Priority Date	Filing Date	Title
SE8203041A SE453514B (sv)	1982-05-14	1982-05-14	Sett att bestemma deoxitymidinkinas-dtk-isoenzymnivaer i kroppsvetska eller cellprov och anvendningen av forfarandet for isoenzymtypning
DE8383850122T DE3376272D1 (en)	1982-05-14	1983-05-10	A method of determining dtk isoenzyme activity and the use thereof
PCT/SE1983/000190 WO1983004054A1 (fr)	1982-05-14	1983-05-10	PROCEDE DE DETERMINATION DE L'ACTIVITE ISOENZYMATIQUE DE LA DESOXYTHYMIDINE KINASE (dTk) ET SON UTILISATION DANS LE DIAGNOSTIC DE MALADIES
JP58501735A JPS59500796A (ja)	1982-05-14	1983-05-10	ｄＴｋアイソザイム活性の測定法とその利用
US06/576,375 US4637977A (en)	1982-05-14	1983-05-10	Method of determining dTk isoenzyme activity and the use thereof
AT83850122T ATE33504T1 (de)	1982-05-14	1983-05-10	Verfahren zur feststellung der dtk isoenzymaktivit\|t und anwendung des verfahrens.
EP83850122A EP0094923B1 (fr)	1982-05-14	1983-05-10	Procédé de détermination de l'activité de l'isoenzyme dTk et son utilisation
AU15540/83A AU551176B2 (en)	1982-05-14	1983-05-10	A method for determination of deoxythymidine kinase (dtk) isoenzyme activity and use thereof for the diagnosis of diseases
CA000428172A CA1199858A (fr)	1982-05-14	1983-05-13	Methode de dosage de l'activite de l'isoenzyme dtk et utilisation
ES522376A ES8402876A1 (es)	1982-05-14	1983-05-13	Procedimiento para determinar el nivel de isoenzima dtk en una muestra de fluido corporal o celular humana o animal.
FI840134A FI77895C (fi)	1982-05-14	1984-01-13	Foerfarande foer bestaemning av deoxithymidinkinas-isoentsymaktivitet och dess anvaendning foer diagnosis av sjukdomar.
NO840117A NO165599C (no)	1982-05-14	1984-01-13	En metode for bestemmelse av dtk isoenzym-aktivitet og anvendelse av denne for in vitro diagnostisering av sykdommer
DK016384A DK167692B1 (da)	1982-05-14	1984-01-13	Fremgangsmaade til bestemmelse af deoxythymidinkinase (dtk)isoenzymniveauer samt anvendelse af fremgangsmaaden

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE8203041A SE453514B (sv)	1982-05-14	1982-05-14	Sett att bestemma deoxitymidinkinas-dtk-isoenzymnivaer i kroppsvetska eller cellprov och anvendningen av forfarandet for isoenzymtypning

Publications (2)

Publication Number	Publication Date
SE8203041L SE8203041L (sv)	1983-11-15
SE453514B true SE453514B (sv)	1988-02-08

Family

ID=20346817

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE8203041A SE453514B (sv)	1982-05-14	1982-05-14	Sett att bestemma deoxitymidinkinas-dtk-isoenzymnivaer i kroppsvetska eller cellprov och anvendningen av forfarandet for isoenzymtypning

Country Status (12)

Country	Link
US (1)	US4637977A (fr)
EP (1)	EP0094923B1 (fr)
JP (1)	JPS59500796A (fr)
AT (1)	ATE33504T1 (fr)
AU (1)	AU551176B2 (fr)
CA (1)	CA1199858A (fr)
DE (1)	DE3376272D1 (fr)
DK (1)	DK167692B1 (fr)
ES (1)	ES8402876A1 (fr)
FI (1)	FI77895C (fr)
SE (1)	SE453514B (fr)
WO (1)	WO1983004054A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816410A (en) *	1986-10-29	1989-03-28	Coulter Corporation	Control slide for immunoassay kit and method of making same
DE60217665T2 (de) *	2002-07-27	2007-10-11	Diasorin Ab	Verfahren zur Bestimmung der Aktivität von Thymidinkinase-1 und dessen Verwendung
KR101275585B1 (ko)	2005-02-25	2013-06-19	뢴네르볼 인터내셔널 아베	티미딘 키나아제 활성을 결정하는 방법 및 키트 및 그의용도
JP7560482B2 (ja) *	2019-05-06	2024-10-02	アロセルエービー	呼吸器感染の検出および分類

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4302535A (en) *	1979-09-27	1981-11-24	Massachusetts Institute Of Technology	Assay for mutagenesis in heterozygous diploid human lymphoblasts
US4317877A (en) *	1980-06-05	1982-03-02	Sloan Kettering Institute	Process for detecting the presence of malignant and pre-malignant cells in humans
IE64317B1 (en) *	1989-10-26	1995-07-26	Walbro Corp	Fuel metering method and apparatus

1982
- 1982-05-14 SE SE8203041A patent/SE453514B/sv not_active IP Right Cessation
1983
- 1983-05-10 AT AT83850122T patent/ATE33504T1/de not_active IP Right Cessation
- 1983-05-10 AU AU15540/83A patent/AU551176B2/en not_active Ceased
- 1983-05-10 DE DE8383850122T patent/DE3376272D1/de not_active Expired
- 1983-05-10 US US06/576,375 patent/US4637977A/en not_active Expired - Lifetime
- 1983-05-10 WO PCT/SE1983/000190 patent/WO1983004054A1/fr not_active Ceased
- 1983-05-10 JP JP58501735A patent/JPS59500796A/ja active Granted
- 1983-05-10 EP EP83850122A patent/EP0094923B1/fr not_active Expired
- 1983-05-13 CA CA000428172A patent/CA1199858A/fr not_active Expired
- 1983-05-13 ES ES522376A patent/ES8402876A1/es not_active Expired
1984
- 1984-01-13 DK DK016384A patent/DK167692B1/da not_active IP Right Cessation
- 1984-01-13 FI FI840134A patent/FI77895C/fi not_active IP Right Cessation

Also Published As

Publication number	Publication date
EP0094923A2 (fr)	1983-11-23
EP0094923B1 (fr)	1988-04-13
DK16384D0 (da)	1984-01-13
SE8203041L (sv)	1983-11-15
DK16384A (da)	1984-01-13
FI840134A7 (fi)	1984-01-13
ATE33504T1 (de)	1988-04-15
AU1554083A (en)	1983-12-02
JPS59500796A (ja)	1984-05-10
AU551176B2 (en)	1986-04-17
US4637977A (en)	1987-01-20
FI77895C (fi)	1989-05-10
ES522376A0 (es)	1984-03-01
CA1199858A (fr)	1986-01-28
FI840134A0 (fi)	1984-01-13
FI77895B (fi)	1989-01-31
JPH051000B2 (fr)	1993-01-07
ES8402876A1 (es)	1984-03-01
WO1983004054A1 (fr)	1983-11-24
EP0094923A3 (en)	1985-07-24
DE3376272D1 (en)	1988-05-19
DK167692B1 (da)	1993-12-06

Legal Events

Date

Code

Title

Description

1995-01-31

NUG

Patent has lapsed

Ref document number: 8203041-2

Effective date: 19910123

Format of ref document f/p: F

Publication	Publication Date	Title
US20230272476A1 (en)	2023-08-31	Nano46 genes and methods to predict breast cancer outcome
EP1996940B1 (fr)	2011-12-21	Détection d'un cancer par dépistage de taux élevés de bcl-2
Maloney et al.	1973	Distribution of suboptimally induced β-D-Galactosidase in Escherichia coli: the enzyme content of individual cells
US20170370933A1 (en)	2017-12-28	Methods and compositions for immunomodulation
Viscidi et al.	1987	Molecular diagnosis of infectious diseases by nucleic acid hybridization
Goldstein et al.	1972	Cystathionine synthase activity in human lymphocytes: induction by phytohemagglutinin
Bartram et al.	2020	Monitoring MRD in ALL: methodologies, technical aspects and optimal time points for measurement
Tiwari et al.	2003	Application of enzyme amplified mycobacterial DNA detection in the diagnosis of pulmonary & extra-pulmonary tuberculosis
CN105648058A (zh)	2016-06-08	一种评估肝癌预后的试剂盒
Zhong et al.	2001	Gross elevation of TT virus genome load in the peripheral blood mononuclear cells of cancer patients
Sprouse et al.	2000	T-Cell Clonality Determination Using Polymerase ChainReaction (PCR) Amplification of the T-Cell Receptorgamma-Chain Gene and Capillary Electrophoresis ofFluorescently Labeled PCR Products
US20160115551A1 (en)	2016-04-28	Methods to predict risk of recurrence in node-positive early breast cancer
Hong et al.	2014	Detection of herpes simplex and varicella‐zoster virus in clinical specimens by multiplex real‐time PCR and melting curve analysis
Fisher et al.	2022	Programmed cell death ligand 1 expression in aggressive pediatric non-Hodgkin lymphomas: frequency, genetic mechanisms, and clinical significance
WO2007089880A2 (fr)	2007-08-09	Méthode de détection de cellules mammaires cancéreuses
US10191048B2 (en)	2019-01-29	Fluorometric immunoassay for detection of anti-dsDNA antibodies
Fox et al.	1980	Sensitivity of leukemic human null lymphocytes to deoxynucleosides
CN102634572A (zh)	2012-08-15	一种荧光定量RT-PCR检测融合基因E2A-PBX1 mRNA表达的试剂盒
US20160046997A1 (en)	2016-02-18	Biomarkers for cervical cancer
Nakamichi et al.	2007	Correlation between promoter hypermethylation of GSTP1 and response to chemotherapy in diffuse large B cell lymphoma
SE453514B (sv)	1988-02-08	Sett att bestemma deoxitymidinkinas-dtk-isoenzymnivaer i kroppsvetska eller cellprov och anvendningen av forfarandet for isoenzymtypning
Escherich et al.	2011	The long-term impact of in vitro drug sensitivity on risk stratification and treatment outcome in acute lymphoblastic leukemia of childhood (CoALL 06-97)
Rosano et al.	1976	Evaluation of adenosine 5'-monophosphate and fluoride as adenylate kinase inhibitors in the creatine kinase assay.
CN104195255A (zh)	2014-12-10	一种检测融合基因AML1-ETO mRNA表达的试剂盒及其检测方法
Yu et al.	2005	Thymidylate synthase predicts for clinical outcome in invasive breast cancer